Gefitinib: all 239 studies that test it
Page 1 of 3. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerNot yet recruitingNCT07829926Phase 2
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingNCT07477457Phase 2
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruitingNCT07458919Early Phase 1
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingNCT06071013Phase 1/2
- Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFRNot yet recruitingNCT03381430Not applicable
- Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC PatientsNot yet recruitingNCT03203590Phase 3
- DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03599518Phase 1Results posted
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerTerminatedNCT03292133Phase 2Results posted
- Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results posted
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)CompletedNCT01982955Phase 1/2Results posted
- A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedNCT01610336Phase 2Results posted
- A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy AloneCompletedNCT01544179Phase 3Results posted
- Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous TreatmentCompletedNCT01530334Phase 2Results posted
- Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung CancerCompletedNCT01404260Phase 3Results posted
- Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedNCT01310855Phase 2Results posted
- Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLCCompletedNCT01203917Phase 4Results posted
- Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck CancerCompletedNCT01185171Phase 2Results posted
- Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00824746Phase 2Results posted
- Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)CompletedNCT00770588Phase 4Results posted
- SELINE: Second-Line Iressa Phase IV Study in NSCLC PatientsCompletedNCT00608868Phase 4Results posted
- Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor GeneCompletedNCT00588445Phase 2Results posted
- Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00536107Phase 4Results posted
- Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and NeckCompletedNCT00519077Phase 2Results posted
- Iressa Study in Patients With Salivary Gland CancerCompletedNCT00509002Phase 2Results posted
- Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By SurgeryTerminatedNCT00493025Phase 2Results posted
- Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedNCT00483561Phase 2Results posted
- Iressa and Taxotere Study in Patients With Metastatic Urothelial CancerTerminatedNCT00479089Phase 2Results posted
- Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00467077Phase 2Results posted
- Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-SmokersCompletedNCT00409006Phase 2Results posted
- Iressa Follow-up TrialCompletedNCT00357734Phase 3Results posted
- Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck CancerCompletedNCT00352105Phase 1/2Results posted
- First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT00344773Phase 2Results posted
- ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung CancerCompletedNCT00328562Phase 1Results posted
- First Line IRESSA™ Versus Carboplatin/Paclitaxel in AsiaCompletedNCT00322452Phase 3Results posted
- Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00317772Phase 1/2Results posted
- Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction CancerCompletedNCT00268346Phase 2Results posted
- Phase II Iressa & Carbo/Gem in NSCLCCompletedNCT00264498Phase 2Results posted
- Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung CancerCompletedNCT00231465Phase 2Results posted
- IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00229723Phase 2Results posted
- Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell CarcinomaCompletedNCT00113529Phase 1/2Results posted
- Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular CorrelatesTerminatedNCT00104728Not applicableResults posted
- Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung CancerCompletedNCT00096486Phase 1/2Results posted
- Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine TherapyCompletedNCT00095836Phase 2Results posted
- Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck CancerTerminatedNCT00088907Phase 3Results posted
- Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast CancerCompletedNCT00086957Phase 1/2Results posted
- Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate CancerCompletedNCT00085566Phase 1/2Results posted
- ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the SkinCompletedNCT00054691Phase 2Results posted
- Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryCompletedNCT00049543Phase 3Results posted
- Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed GliomasCompletedNCT00042991Phase 1/2Results posted
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNCT04642547Not applicable
- Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC PatientsStatus unknownNCT04390984Phase 1
- Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M NegativeCompletedNCT03758287Phase 1/2
- To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung AdenocarcinomaStatus unknownNCT03656393Phase 3
- Phase I Study of the Combination of Anlotinib With GefitinibStatus unknownNCT03602027Not applicable
- Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR MutationStatus unknownNCT03486496Phase 2
- S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLCStatus unknownNCT03457337Phase 2
- The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR MutationStatus unknownNCT03399669Phase 2
- A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.Status unknownNCT03381066Phase 3
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
- Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric CancerCompletedNCT03170180Phase 2
- Bone Metastasis on the Survival of Gefitinib Effective PatientsCompletedNCT03157310Not applicable
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03122717Phase 1/2
- Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedNCT03050177Phase 1
- Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedNCT03050164Phase 1
- EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT03002844Phase 2
- A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02976116Phase 2
- Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled TrialStatus unknownNCT02951637Phase 2
- EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT02859077Phase 3
- PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker DiscoveryCompletedNCT02804776Phase 2
- Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung AdenocarcinomaStatus unknownNCT02518802Phase 3
- Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's DiseaseStatus unknownNCT02484755Phase 2
- Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid TumorsCompletedNCT02447419Phase 2
- A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCCompletedNCT02374645Phase 1
- Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIBTerminatedNCT02326285Phase 2/3
- Blood Detection of EGFR Mutation For Iressa TreatmentStatus unknownNCT02282267Not applicable
- Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung CancerStatus unknownNCT02151721Phase 1
- Combination of Chemotherapy and Gefitinib as First-line TreatmentCompletedNCT02148380Not applicable
- MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedNCT02088112Phase 1
- Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsCompletedNCT02040064Phase 1
- Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant NsclcStatus unknownNCT01955421Phase 2
- Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung CancerStatus unknownNCT01951469Phase 3
- Third-line Treatment of Gefitinib in NSCLC PatientsCompletedNCT01933347Phase 2
- CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung CancerTerminatedNCT01871480Phase 2
- Combination of Metformin With Gefitinib to Treat NSCLCCompletedNCT01864681Phase 2
- Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)CompletedNCT01833572Phase 2
- Gefitinib Versus Pemetrexed for Previously Treated NSCLC PatientsCompletedNCT01783834Phase 2
- Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLCStatus unknownNCT01755923Phase 2
- Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer PatientsStatus unknownNCT01749072Phase 2
- The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast CancerStatus unknownNCT01732276Phase 2
- A Study of LY2875358 in Japanese Participants With Advanced CancerCompletedNCT01602289Phase 1
- A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFRCompletedNCT01570296Phase 1
- Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRCompletedNCT01556191Phase 2
- First Line Gefitinib by FDG-PET Metabolic ResponseStatus unknownNCT01510990Phase 2
- Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never SmokersStatus unknownNCT01502202Phase 2
- Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung CancerCompletedNCT01498562Phase 2
- Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line ChemotherapyCompletedNCT01485809Phase 2
- Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to GefitinibTerminatedNCT01405846Phase 2
- Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR MutationStatus unknownNCT01405079Phase 3
- Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain MetastasisTerminatedNCT01363557Not applicable
- Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal CancerStatus unknownNCT01291823Phase 2